It’s a bad pun that can’t be avoided: The Chinese are knocking off genes as well as jeans. What’s more, Chinese companies may be infringing on the patents of U.S. companies before the U.S. company has even received approval to bring the product to market in the United States.
Last year, it was reported that SiBiono Gentech Co. Ltd. in Shenzhen was treating patients successfully for head and neck cancer with its gene replacement therapy, and that Americans were traveling to China to get the medicine. SiBiono’s therapy uses a virus to deliver to tumors a gene called p53, a naturally occurring tumor suppressor that helps destroy cancerous cells. Introgen Therapeutics, Inc., a biotech company based in Austin, claims the Chinese drug is a rip-off of its own drug Advexin, developed using patents licensed from the M.D. Anderson Medical Center of the University of Texas. Introgen has been working on the treatment for 15 years and is now in phase-three clinical trials in the U.S.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
